While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss is a common goal for many, and while diet and exercise remain essential, some turn to medications like Mounjaro ...

Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...

Gemma Collins reveals weight loss with Mounjaro injections, showcasing a new look and expressing newfound confidence.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Tori Spelling's alarming weight loss has sparked growing concerns, with many fearing her drastic transformation could be ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The natural Mounjaro drink has no scientific backing for weight loss effects comparable to FDA-approved tirzepatide While safe to consume, it lacks essential nutrients and shouldn't replace ...